Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, 2-Part Study to Evaluate the Bioequivalence of the Duvelisib Marker-Image Formulation to the Duvelisib Clinical-Trial Formulation and to Assess the Effect of Food on the Pharmacokinetics of IP Duvelisib in Healthy Adult Subjects

Next Previous
Trial Profile

A Phase 1, Open-label, 2-Part Study to Evaluate the Bioequivalence of the Duvelisib Marker-Image Formulation to the Duvelisib Clinical-Trial Formulation and to Assess the Effect of Food on the Pharmacokinetics of IP Duvelisib in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Allergic asthma; Chronic lymphocytic leukaemia; Follicular lymphoma; Haematological malignancies; Non-Hodgkin's lymphoma; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Infinity Pharmaceuticals; Secura Bio; Verastem; Verastem Oncology

Most Recent Events

  • 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
  • 13 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
  • 28 Aug 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top